20/20 Biolabs Common Stock Overview
Valuation check: AIDX's P/E ratio is -0.73, below the sector sector average of 44.85.
Get informed when a big investor buys or sells
+ Follow-0.73
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for AIDX is -0.73. That is below the sector sector average of 44.85. Investors often review this figure alongside 20/20 Biolabs Common Stock's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, AIDX currently prints -0.73 for P/E ratio, while the sector average sits near 44.85. That is roughly 101.6% below the sector mean. Large gaps often invite a closer look at 20/20 Biolabs Common Stock's growth, margins, and balance sheet.
A P/E ratio of -0.73 for 20/20 Biolabs Common Stock is not 'good' or 'bad' on its own. Compare it with the peer average (44.85) and with AIDX's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting AIDX's P/E ratio (-0.73), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
